NCCM
NBIX icon

Nine Chapters Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Nine Chapters Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-76,600
Closed -$715K – 913
2013
Q4 		$715K Buy
76,600
+55,400
+261% +$541K 0.07% 380
2013
Q3 		$240K Buy
+21,200
New +$291K 0.03% 594

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Nine Chapters Capital Management's NBIX Position: Q1 2014 in Review

Nine Chapters Capital Management sold out of Neurocrine Biosciences (NBIX) in Q1 2014, closing a stake of 76,600 shares — an estimated $715K sold.

Nine Chapters Capital Management first reported a position in NBIX in Q3 2013 and held it in 2 quarters. The position peaked at $715K in Q4 2013. 121 funds tracked by Wall St. Rank hold NBIX as of Q1 2014.

  • Nine Chapters Capital Management reported no remaining Neurocrine Biosciences position as of Q1 2014 after selling out during the quarter.
  • Nine Chapters Capital Management sold 76,600 Neurocrine Biosciences shares in Q1 2014, an estimated $715K.
  • Nine Chapters Capital Management first reported a position in Neurocrine Biosciences in Q3 2013 and held it in 2 quarters.
  • Nine Chapters Capital Management's Neurocrine Biosciences position peaked at $715K in Q4 2013.
  • 121 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2014.

Based on Nine Chapters Capital Management's 13F filing for Q1 2014, filed 15 May 2014.